Alpha Cognition Reports Fiscal 2025 Financial Results and Operational Update
Alpha Cognition Inc. Announces Fiscal 2025 Financial Results and Operational Progress Update Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has reported its…
Agenus to Host March 2026 Webcast on Advancing BOT + BAL Immunotherapy Across Tumors
Agenus to Host March 2026 Stakeholder Webcast Highlighting Progress of BOT + BAL Immunotherapy and Expanding Patient Access Across Multiple Tumor Types Agenus Inc., a biotechnology company focused on advancing…
Biocytogen Announces U.S. Food and Drug Administration IND Clearance for NEOK Bio’s NEOK002 Targeting Solid Tumors
Biocytogen Announces U.S. Food and Drug Administration IND Clearance for Partner NEOK Bio’s NEOK002 in Solid Tumor Indications Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced a significant regulatory milestone achieved…
Long Bridge Medical Gets FDA Clearance to Begin U.S. Pivotal Study of LensOne Prosthetic Capsular Bag
Long Bridge Medical Secures U.S. Food and Drug Administration Clearance to Launch Pivotal U.S. Study of LensOne Prosthetic Capsular Bag Long Bridge Medical, Inc. has reached an important regulatory milestone…
Bio-Techne Expands COMET™ Suite with Modular Innovations to Advance Spatial Biology
Bio-Techne Expands Spatial Biology Capabilities with Modular Enhancement of the COMET™ Suite Bio-Techne Corporation has announced a significant expansion of its spatial biology capabilities with the introduction of new tools…
WuXi Biologics Reports Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Innovation
WuXi Biologics Announces Record 2025 Annual Results, Fueled by Operational Excellence and Digital-Native Infrastructure WuXi Biologics has reported strong financial and operational performance for 2025, marking a year of significant…
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot
Pet Partners and Baxter Foundation Expand Therapy Animal Programs to Reach 100,000 Patients and Healthcare Workers in Two-Year Pilot Pet Partners and the Baxter Foundation, the charitable arm of Baxter…
Merck & Co. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML)
Merck & Co., Inc. to Acquire Terns Pharmaceuticals, Inc., Strengthening Hematology Pipeline with TERN-701 for Chronic Myeloid Leukemia (CML) Merck & Co.—known as MSD outside the United States and Canada—and…
Novo Nordisk’s UBT251 Delivers Up to 2.16% HbA1c Reduction in Phase 2 Type 2 Diabetes Trial
Novo Nordisk A/S Reports Up to 2.16% HbA1c Reduction with Triple Agonist UBT251 After 24 Weeks in Phase 2 Trial Among Chinese Patients with Type 2 Diabetes The United Laboratories…
Kallisio Secures CE Mark Approval for Stentra™ Precision Oral Immobilization System
Kallisio Secures CE Mark for Stentra™ Precision Oral Immobilization System Kallisio has announced a significant regulatory milestone with the CE certification of its innovative Stentra intraoral positioning system under the…
Aerin Medical Exceeds 200,000 Patients Treated with Its Minimally Invasive Therapies for Chronic Nasal Conditions
Aerin Medical Achieves Milestone of Treating Over 200,000 Patients with Its Minimally Invasive Therapies for Chronic Nasal Disorders Aerin Medical Inc., a recognized innovator in minimally invasive therapies for chronic…
FDA Approves Corcept’s Lifyorli™ Combo for Platinum-Resistant Ovarian Cancer
FDA Clears Corcept’s Lifyorli™ (relacorilant) in Combination with Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer Treatment Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy,…